FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Plesha Scott M.
2. Issuer Name and Ticker or Trading Symbol

BIODELIVERY SCIENCES INTERNATIONAL INC [ BDSI ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
See Remarks
(Last)          (First)          (Middle)

C/O BIODELIVERY SCIENCES INTL, INC.,, 4131 PARKLAKE AVE. SUITE 225
3. Date of Earliest Transaction (MM/DD/YYYY)

1/27/2022
(Street)

RALEIGH, NC 27612
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/27/2022  M  21050 A$0 320924 D  
Common Stock 1/31/2022  M  10869 A$0 331793 D  
Common Stock 1/31/2022  M  13334 A$0 345127 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (right to buy) $3.66 (1)1/27/2022  A (2)  369721     (2)1/26/2032 Common Stock 369721.0 $3.66 369721 D  
Restricted Stock Units $0.0 1/27/2022  A (3)  66257     (4)1/27/2025 Common Stock 66257.0 $0 66257 D  
Restricted Stock Units $0.0 1/27/2022  M     21050   (5)1/27/2024 Common Stock 21050.0 $0 42101 D  
Restricted Stock Units $0.0 1/29/2022  M     10869   (6)1/29/2023 Common Stock 10869.0 $0 10870 D  
Restricted Stock Units $0.0 1/31/2022  M     13334   (7)1/31/2022 Common Stock 13334.0 $0 0 D  

Explanation of Responses:
(1) The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022.
(2) The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
(3) The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
(4) Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.
(5) The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 27, 2021, under the Plan. The remaining RSUs will vest in equal portions on: (i) January 27, 2023; and (ii) January 27, 2024.
(6) The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 29, 2020, under the Plan. The remaining RSUs vest on January 29, 2023.
(7) The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan.

Remarks:
President and Chief Commercial Officer

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Plesha Scott M.
C/O BIODELIVERY SCIENCES INTL, INC.,
4131 PARKLAKE AVE. SUITE 225
RALEIGH, NC 27612


See Remarks

Signatures
/s/ Scott Plesha1/31/2022
**Signature of Reporting PersonDate

BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more BioDelivery Sciences Charts.
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more BioDelivery Sciences Charts.